(Q43677692)

25 November 2017

title

A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation (English)

1 reference

25 November 2017

1 reference

M Carrier

1

1 reference

25 November 2017

M White

2

1 reference

25 November 2017

L P Perrault

3

1 reference

25 November 2017

G B Pelletier

4

1 reference

25 November 2017

M Pellerin

5

1 reference

25 November 2017

D Robitaille

6

1 reference

25 November 2017

L C Pelletier

7

1 reference

25 November 2017

publication date

1 December 1999

1 reference

The Journal of Heart and Lung Transplantation

25 November 2017

published in

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

12

1 reference

25 November 2017

page(s)

1218-1223

1 reference

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2899%2900100-X

7 January 2021

10.1016/S1053-2498(99)00100-X

Identifiers

DOI

1 reference

25 November 2017

1 reference